MediGene AG has initiated a clinical Phase I/II trial of the drug candidate NV1020 for the treatment of liver metastases developing from colorectal cancer.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content